logo

SPRB

SpruceยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

SPRB Profile

Spruce Biosciences, Inc.

A clinical late stage biopharmaceutical company focused on developing and commercializing new therapies for rare endocrine disorders

Pharmaceutical
--
09/15/2025
NASDAQ Stock Exchange
21
12-31
Common stock
611 Gateway Boulevard, Suite 740, South San Francisco, California 94080
--
Spruce Biosciences, Inc., was originally incorporated as a limited liability company in Delaware in November 2014. The company is a late-stage biopharmaceutical company focused on developing and commercializing new therapies for rare endocrine diseases with unmet medical needs. The company is initially developing a wholly-owned product candidate, tildacerfont, as a potential first non-steroidal therapy to provide significantly improved disease control and reduced steroid burden for patients with typical congenital adrenal hyperplasia.